Trastuzumab + Pertuzumab

DRUG3 trials

Sponsors

Massachusetts General Hospital, Seoul National University Bundang Hospital, Henan Cancer Hospital

Conditions

Advanced Solid TumorBreast CancerMetastatic CancerMetastatic Colon CancerSolid TumorStage III Colon Cancer

Phase 3

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

RecruitingNCT03803553

Massachusetts General HospitalMetastatic Colon Cancer, Stage III Colon Cancer

Start: 2020-04-16End: 2027-12-31Target: 400Updated: 2025-12-23

Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

RecruitingNCT07057427

Henan Cancer HospitalBreast Cancer

Start: 2025-06-24End: 2029-06-30Target: 812Updated: 2025-07-09

Unknown Phase

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

RecruitingNCT05525858

Seoul National University Bundang HospitalAdvanced Solid Tumor, Metastatic Cancer, Solid Tumor

Start: 2022-09-28End: 2027-03-31Target: 1000Updated: 2025-04-27

Related Papers

Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.

2024-05-093 citations

Early identification and treatment of occult metastatic disease in stage III colon cancer (SU2C ACT3 clinical trial).

Journal of Clinical Oncology2024-01-209 citations

Korean Precision Medicine Networking Group study of molecular profiling guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) II (KCSG AL 22-09).

Journal of Clinical Oncology2023-06-011 citations

ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)

BMC Cancer2023-03-2026 citations

BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer

BMJ Open2021-09-0142 citations

Abstract A024: Preventing PROGRESSION

Cancer Epidemiology Biomarkers & Prevention2020-06-01